个体水平模拟预测心血管新药在常规诊疗人群中的有效性与安全性
在存在治疗效应异质性(HTE)时,随机对照试验(RCT)的平均治疗效应可能不适用于不同患者。本研究开发个体水平模拟方法,以RE-LY试验和两项比较达比加群与华法林观察性研究为基础,建立并验证可复现RE-LY中缺血性卒中和大出血发生率的模拟模型,并预测RCT在类似观察性研究人群中开展的可能结果。
要点
- 个体水平模拟可扩展RCT结果至常规诊疗人群。
- 模拟模型复现了RE-LY中缺血性卒中和大出血发生率。
- 方法用于预测RCT在观察性研究人群中的结果。
核心结论
- 利用个体水平模拟可在存在治疗效应异质性时将RCT结果扩展至目标患者人群。
研究设计与样本
- 基于RE-LY试验和两项比较达比加群与华法林用于房颤患者的观察性研究,开发个体水平模拟模型。
主要发现
- 模拟模型复现了RE-LY试验中观察到的缺血性卒中和大出血发生率。
- 验证后的模拟模型用于预测RCT在类似观察性研究人群中开展的可能结果。
临床怎么用
- 临床药师可关注个体水平模拟方法,用于评估RCT平均效应在常规诊疗人群中的适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the presence of heterogeneity of treatment effect (HTE), the average treatment effect from a randomized controlled trial (RCT) may not be applicable to different patients, such as those in observational settings. Our objective was to develop a novel approach that uses individual-level simulation to expand RCT results to target patient populations in the presence of HTE. For this purpose, we compared the results of the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, and two observational studies that compared benefits and risks of dabigatran to warfarin in patients with atrial fibrillation. We developed a simulation model that replicates the rates of ischemic stroke and major bleeding observed in RE-LY using published outcome risk models and participants' baseline characteristics. We used our validated simulation model to predict what the results of the RCT would have been had it been conducted in populations similar to those in the observational studies.
引用
- Najafzadeh M, Schneeweiss S, Choudhry NK, et al. Simulation for Predicting Effectiveness and Safety of New Cardiovascular Drugs in Routine Care Populations. Clin Pharmacol Ther. 2018. PMID: 29424437. doi:10.1002/cpt.1045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。